Literature DB >> 6321599

A sensitive enzyme-linked immunosorbent assay (ELISA) against the major EBV-associated antigens. I. Correlation between ELISA and immunofluorescence titers using purified antigens.

J Luka, R C Chase, G R Pearson.   

Abstract

An enzyme-linked immunosorbent assay (ELISA) was developed for the major Epstein-Barr virus (EBV) associated antigens. The ELISA assay was based on purified protein components of virus-capsid antigen (VCA), early antigen (EA), membrane antigen (MA) and the nuclear antigen (EBNA). These antigens, except EBNA, were purified on immunoaffinity columns containing monoclonal antibodies, while EBNA was purified by biochemical methods. Screening of 69 human sera including 26 sera from individuals with infectious mononucleosis against these antigens in ELISA showed a good correlation with immunofluorescence titers against the major groups of EBV associated antigens. The results indicated that the ELISA technique using purified EBV proteins could be useful for detecting and monitoring antibody responses to different EBV proteins in patients with EBV-associated diseases.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6321599     DOI: 10.1016/0022-1759(84)90093-0

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  20 in total

Review 1.  Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years.

Authors:  Ralf D Hess
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

2.  Characterization of the restricted component of Epstein-Barr virus early antigens as a cytoplasmic filamentous protein.

Authors:  J Luka; G Miller; H Jörnvall; G R Pearson
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

3.  Expression of an early Epstein-Barr virus antigen (EA-D) in E. coli. Brief report.

Authors:  D Roeckel; H Boos; N Mueller-Lantzsch
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

4.  Characterization of a major protein with a molecular weight of 160,000 associated with the viral capsid of Epstein-Barr virus.

Authors:  B Vroman; J Luka; M Rodriguez; G R Pearson
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

5.  Application of a commercial immunoblot to define EBV IgG seroprofiles.

Authors:  Fernando de Ory; Eulalia Guisasola; David Tarragó; Juan Carlos Sanz
Journal:  J Clin Lab Anal       Date:  2014-03-28       Impact factor: 2.352

6.  EBNA-1: a virally induced nuclear antigen of primate lymphocytes and its expression in Drosophila cells.

Authors:  A J MacGillivray; M J Allday; S E Saunders; J H Sinclair
Journal:  Br J Cancer Suppl       Date:  1988-12

7.  Decreased T cell precursor frequencies to Epstein-Barr virus glycoprotein Gp110 in peripheral blood correlate with disease activity and severity in patients with rheumatoid arthritis.

Authors:  E Toussirot; D Wendling; P Tiberghien; J Luka; J Roudier
Journal:  Ann Rheum Dis       Date:  2000-07       Impact factor: 19.103

8.  Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220.

Authors:  T Sairenji; G Bertoni; M M Medveczky; P G Medveczky; Q V Nguyen; R E Humphreys
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

9.  Increased risk of malignant lymphoma indicated by elevated Epstein-Barr virus antibodies--a prospective study.

Authors:  T Lehtinen; J Lumio; J Dillner; M Hakama; P Knekt; M Lehtinen; L Teppo; P Leinikki
Journal:  Cancer Causes Control       Date:  1993-05       Impact factor: 2.506

10.  Carboxyl-terminal domain of the Epstein-Barr virus nuclear antigen is highly immunogenic in man.

Authors:  G Milman; A L Scott; M S Cho; S C Hartman; D K Ades; G S Hayward; P F Ki; J T August; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.